| 319 | For the treatment of Paget's disease. |
| | LU Authorization Period: Indefinite. |
| 436 | For the treatment of osteoporosis in postmenopausal females who meet the following criteria:
- High risk* for fracture; and
- For whom oral bisphosphonates are contraindicated due to abnormalities of the esophagus (e.g. esophageal stricture or achalasia) OR inability to stand or sit upright for at least 30 minutes.
*High fracture risk is defined as either:
- a prior fragility fracture AND a moderate 10-year fracture risk (10% to 20%) based on the Canadian Association of Radiologists and Osteoporosis Canada (CAROC) tool or the Fracture Risk Assessment (FRAX) tool; OR
- a high 10-year fracture risk (greater than or equal to 20%) based on the CAROC or FRAX tool; OR
- where a patient's 10-year fracture risk based on the CAROC or FRAX tool, is less than the thresholds defined above, a high fracture risk based on evaluation of clinical risk factors for fracture
Note: Use of the CAROC or FRAX tool may underestimate fracture risk in certain circumstances and may not include all risk factors. |
| | LU Authorization Period: Indefinite. |
| 523 | For the treatment of osteoporosis in males who meet the following criteria:
- High risk* for fracture; and
- For whom oral bisphosphonates are contraindicated due to abnormalities of the esophagus (e.g. esophageal stricture or achalasia) OR inability to stand or sit upright for at least 30 minutes.
*High fracture risk is defined as either:
- a moderate 10-year fracture risk (10% to 20%) with a prior fragility fracture based on the Canadian Association of Radiologists and Osteoporosis Canada (CAROC) tool or the Fracture Risk Assessment (FRAX) tool; OR
- a high 10-year fracture risk (greater than or equal to 20%) based on the CAROC or FRAX tool; OR
- where the patient's 10-year fracture risk is below 10% based on the CAROC or FRAX tool, a high fracture risk based on evaluation of clinical risk factors for fracture
Note: Use of the CAROC or FRAX tool may underestimate fracture risk in certain circumstances and may not include all risk factors. |
| | LU Authorization Period: Indefinite. |
| | NOTE: In all cases, patients receiving Aclasta should not be receiving concomitant bisphosphonate therapy. The recommended dose of Aclasta (zoledronic acid) is a single IV injection of 5mg, once yearly. |
